<DOC>
	<DOC>NCT02502162</DOC>
	<brief_summary>The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to come to several visits, which will include sensory testing, physical assessments, and questionnaires.</brief_summary>
	<brief_title>Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Upper and/or lower extremity CRPS On stable treatment for 3 months CRPS for at least 1 year Meet the Budapest criteria for CRPS at time of the study. Any known allergy to naltrexone or naloxone Use of prescription opioid analgesics or illegal opioid use Current of planned pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>